Using Ovality to Predict Nonmutagenic, Orally Efficacious Pyridazine Amides as Cell Specific Spleen Tyrosine Kinase Inhibitors

Citations Over TimeTop 21% of 2014 papers

Abstract

Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of cancers and autoimmune diseases such as asthma, rheumatoid arthritis, and systemic lupus erythematous. We report the structure-guided optimization of pyridazine amide spleen tyrosine kinase inhibitors. Early representatives of this scaffold were highly potent and selective but mutagenic in an Ames assay. An approach that led to the successful identification of nonmutagenic examples, as well as further optimization to compounds with reduced cardiovascular liabilities is described. Select pharmacokinetic and in vivo efficacy data are presented.

Related Papers

• → Aerosolized Syk Antisense Suppresses Syk Expression, Mediator Release from Macrophages, and Pulmonary Inflammation(2000)73 cited
• → Rapid ubiquitination of Syk following GPVI activation in platelets(2005)63 cited
• → Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice(2019)26 cited
• → Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs(2016)12 cited
• → SYK κινάση της τυροσίνης. Έκφραση και ρόλος της στον καρκίνο του μαστού(2005)